Measurable residual disease in acute lymphoblastic leukemia: How low is low enough?
{{output}}
Quantification of measurable residual disease (MRD) in acute lymphoblastic leukemia (ALL) is a well-established clinical tool used to risk stratify patients during the course of chemotherapy, immunotherapy, and/or transplant therapy. As technologies evolve, th... ...
